These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 17195576)

  • 1. Reimbursement decision-making and prescription patterns of glitazones in treatment of type 2 diabetes mellitus patients in Denmark.
    Iversen PB; Vondeling H
    Health Care Anal; 2006 Jun; 14(2):79-89. PubMed ID: 17195576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reimbursement of glitazones in treatment of type 2 diabetes patients in Denmark in the context of a voluntary system for submitting pharmacoeconomic studies.
    Vondeling H; Iversen PB
    Eur J Health Econ; 2004 Oct; 5(3):263-9. PubMed ID: 15714347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A lifetime modelled economic evaluation comparing pioglitazone and rosiglitazone for the treatment of type 2 diabetes mellitus in the UK.
    Home P; Bagust A; Taylor M; Ambery P; Mendes da Costa S
    Pharmacoeconomics; 2007; 25(9):801-2; author reply 802-5. PubMed ID: 17803338
    [No Abstract]   [Full Text] [Related]  

  • 4. Glitazones in type 2 diabetes: an update.
    Drug Ther Bull; 2008 Apr; 46(4):25-9. PubMed ID: 18403615
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diabetes treatments and risk of heart failure, cardiovascular disease, and all cause mortality: cohort study in primary care.
    Hippisley-Cox J; Coupland C
    BMJ; 2016 Jul; 354():i3477. PubMed ID: 27413012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utilization and costs for compliant patients initiating therapy with pioglitazone or rosiglitazone versus insulin in a Medicaid fee-for-service population.
    Kalsekar I; Iyer S; Mody R; Rajagopalan R; Kavookjian J
    J Manag Care Pharm; 2006 Mar; 12(2):121-9. PubMed ID: 16515370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Is there a need of glitazones in the treatment of diabetes?].
    Halse J
    Tidsskr Nor Laegeforen; 2007 Aug; 127(16):2124; author reply 2124. PubMed ID: 17717584
    [No Abstract]   [Full Text] [Related]  

  • 8. The role of glitazones in management of type 2 diabetes. A dream or a nightmare?
    Lindberg M; Astrup A
    Obes Rev; 2007 Sep; 8(5):381-4. PubMed ID: 17716295
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug safety and the impact of drug warnings: An interrupted time series analysis of diabetes drug prescriptions in Germany and Denmark.
    Hostenkamp G; Fischer KE; Borch-Johnsen K
    Health Policy; 2016 Dec; 120(12):1404-1411. PubMed ID: 27817873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Healthcare costs and prescription adherence with introduction of thiazolidinedione therapy in Medicaid type 2 diabetic patients: a retrospective data analysis.
    Balkrishnan R; Rajagopalan R; Shenolikar RA; Camacho FT; Whitmire JT; Anderson RT
    Curr Med Res Opin; 2004 Oct; 20(10):1633-40. PubMed ID: 15462696
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness analysis of thiazolidinediones in uncontrolled type 2 diabetic patients receiving sulfonylureas and metformin in Thailand.
    Chirakup S; Chaiyakunapruk N; Chaikledkeaw U; Pongcharoensuk P; Ongphiphadhanakul B; Roze S; Valentine WJ; Palmer AJ
    Value Health; 2008 Mar; 11 Suppl 1():S43-51. PubMed ID: 18387067
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The true place of glitazones in the treatment of diabetes: after the PROactive study].
    Lindberg M; Jørgensen PH; Kampmann JP
    Ugeskr Laeger; 2006 Jun; 168(25):2477-9; author reply 2479-80. PubMed ID: 16824389
    [No Abstract]   [Full Text] [Related]  

  • 13. [Glitazones--again].
    Halse J
    Tidsskr Nor Laegeforen; 2007 Oct; 127(20):2707; author reply 2707. PubMed ID: 17952161
    [No Abstract]   [Full Text] [Related]  

  • 14. Self blood glucose monitoring in type 2 diabetes. A financial impact analysis based on UK primary care.
    Belsey JD; Pittard JB; Rao S; Urdahl H; Jameson K; Dixon T
    Int J Clin Pract; 2009 Mar; 63(3):439-48. PubMed ID: 19222629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determinants of prescribing patterns for type II diabetes at Primary Care Trust level.
    Lloyd DC; Scrivener G
    J Clin Pharm Ther; 2004 Aug; 29(4):389-94. PubMed ID: 15271107
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Glitazones in type 2 diabetes--documented risks, uncertain benefits].
    Håkansson J
    Lakartidningen; 2007 Oct 24-30; 104(43):3198-200. PubMed ID: 18018937
    [No Abstract]   [Full Text] [Related]  

  • 17. Which should we ADOPT: sulphonylureas or glitazones?
    Koshiyama H; Inagaki N; Seino Y
    Diabet Med; 2007 Jul; 24(7):804. PubMed ID: 17596243
    [No Abstract]   [Full Text] [Related]  

  • 18. Drug-class-specific changes in the volume and cost of antidiabetic medications in Poland between 2012 and 2015.
    Śliwczyński A; Brzozowska M; Jacyna A; Iltchev P; Iwańczuk T; Wierzba W; Marczak M; Orlewska K; Szymański P; Orlewska E
    PLoS One; 2017; 12(6):e0178764. PubMed ID: 28582404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glitazones in the treatment of diabetes mellitus: clinical outcomes in large scale clinical trials.
    Charbonnel B
    Fundam Clin Pharmacol; 2007 Nov; 21 Suppl 2():19-20. PubMed ID: 18001315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The increase in the use of drug treatment for diabetes mellitus in the Netherlands, 1998-2003].
    Langendam MW; Hooijkaas C; Piepenbrink JF
    Ned Tijdschr Geneeskd; 2006 Jun; 150(25):1396-401. PubMed ID: 16841589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.